For the first time, we observed the improvement of the inflammatory response mediated by NLRP‐3/calpain‐1 as a breakthrough that could scientifically explain the prevention and treatment effects of AS‐IV on pulmonary hypertension. The gene discussed is NLRP3; the disease is pulmonary arterial hypertension.